The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2022 | Molecular characterization of clinical response in patients with AML treated with ivo + aza
Ivosidenib, an IDH1 inhibitor, was shown to significantly improve event-free survival in combination with azacitidine in the Phase III AGILE study (NCT03173248). In this interview, Stéphane de Botton, MD, PhD, Gustave Roussy Institute, Paris, France, discusses the molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia enrolled in the AGILE trial. Improved clinical outcomes with the use of ivosidenib and azacitidine is associated with sustained clearance of the mutant IDH1 clone, including patients with disease that harbors mutations implicated in resistance of ivosidenib monotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
